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TRENDS AND EFFECTS OF PHARMACEUTICAL DTCA

ABSTRACT
Purpose – The purpose of the review is to investigate the current trend of pharmaceutical
Direct-to-Consumer Advertising (DTCA) in the US and its effect on patients, physicians, and
drug utilization. DTCA by pharmaceutical firms may be defined as an attempt by
pharmaceutical companies to advertise products directly to patients.
Design/methodology/approach – Methodology for this paper is a literature review approach.
Findings – Pharmaceutical DTCA demonstrated a reduction in total spending, while the
online channel media experienced growth. DTCA has influenced the physician-patient
relationship and patient satisfaction. Patients who received medication associated with DTCA
showed higher satisfaction. DTCA of second-line drugs increased first-line drug utilization.
Benefits of pharmaceutical DTCA include enhancing appropriate drug utilization and
increasing awareness. DTCA might cause harm by interfering with physician decisions
regarding drug choice.
Research limitations – Limitations include the availability of information on DTCA
spending by pharmaceutical companies and the lack of quantitative data on the effect of
pharmaceutical DTCA. Additionally, DTCA is sometimes affected by research bias.
Practical implication – Improvement in the physician-patient relationship and patient
satisfaction, as well as improvement in the quality of care provided may be demonstrated.
Social implication – Pharmaceutical firms utilizing DTCA marketing advertisement
methodologies can increase awareness of under-diagnosed conditions, affect medication
costs, and the utilization of appropriate drug utilization.
Originality/Value – Literature review highlights current relationships between DTCA,
patients, physicians, and drug utilization to explore the effects DTCA has on consumers.
Keywords – DTCA, Prescription drug coupons, physician/patient relationship,
pharmaceutical advertising, medication utilization
Paper Type – Literature review
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INTRODUCTION
Direct-to-Consumer Advertising (DTCA) of pharmaceutical firms may be defined as an
attempt by the pharmaceutical companies to advertise or promote information regarding
prescription drugs directly to patients. DTCA can be performed through a variety of
advertising channels; for example, television broadcast, billboards, and consumer magazine
(Abel et al., 2006).
There have been several types of DTCA, which have included: help-seeking ads,
reminder ads, and product claim ads. (Ventola, 2011). The help-seeking ads variety has been
categorized by the presence of information regarding a disease while omitting the drug
information. The reminder ads provide limited information regarding prescription
medications, such as the name of a drug, price, and strength. This variety of advertisement
does not provide the indications or any claim on efficacy or any drug effects (Gellad & Lyles,
2007). The product claim ads variety is advertisement involving a more holistic provision of
prescription drug information compared with the other types of advertisement. This kind of
advertisement provides the indication, efficacy, and safety profile of the prescription drug
(Connors, 2009). As some countries have allowed limited prescription drug advertisement,
the U.S. and New Zealand have product claim ads allowing for drug advertisement on
television and other broadcasting media (Abel et al., 2006; Vats, 2014).
The advertisement of prescription drugs via television broadcast has become more
popular as less stringent Food and Drug Administration (FDA) regulations on DTCA began in
1997 (Morgan, 2007). The expenditure of DTCA was higher than $4 billion in 2004 and
showed 23% growth when compared to the previous year (Gellad & Lyles, 2007). Even
though the total spending of prescription drug promotion declined between 2006 and 2010,
DTCA continually receives criticism due to the appropriateness and legal issues. For
example, DTCA has been associated with “black box” warnings of prescription drugs that
may cause serious side effects (Arnold & Oakley, 2013). The purpose of DTCA focuses
mainly on the commercial aspects rather than aiming to educate patients.
DTCA has targeted a limited range of drugs. In 2000, 20 of the top products in the
pharmaceutical industry accounted for 60% of total DTCA spending. Furthermore, the
advertisement of a single medication, Vioxx was reported at $161 million in 2000, which
surpassed many of the advertisement expenditures for consumer products such as Dell,
Budweiser, Pepsi, and Nike (Rosenthal, Berndt, Donohue, Frank, & Epstein, 2002). In
September 2004, after the discovery of severe side effects of Vioxx, (including stroke and
myocardial infarction), the drug was withdrawn from the market (Schuchman, 2007).
Critics assert that DTCA is under-regulated and urge the need to strengthen
regulations (Donahue, Cervasco, & Rosenthal, 2007). For example, the advertisement of
prescription drugs requires no approval or any pre-clearance (pre-screening) before the time
of broadcasting. In the event violation(s) of FDA regulations occur, the FDA could request
revision of the advertisement; however, it would not change the fact that consumers have
already been exposed to inappropriate advertising and possibly misled by the information
provided (Shaw, 2008). Additionally, FDA regulatory guidance of DTCA by pharmaceutical
firms is often perceived as unclear. For instance, the guidance only requires the
pharmaceutical companies to include the most serious and the most common side effects of
their products. Thus, allowing the pharmaceutical companies to decide which associated risks
to disclose in their advertisement (Biegler & Vargas, 2013). Furthermore, critics point out the
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establishment of DTCA guidance has been delayed for years. In 2004, a draft version for new
guidance regarding risk communication was written, yet never received revision until 2015
(Christopher & Robertson, 2015).
DTCA impacts the public in both favorable and harmful ways (Almasi, Stafford,
Kravitz, & Mansfield, 2006). The benefits of DTCA for the public have included; more
empowered patients, enhancement in patient-physician relationship, and increased awareness
to patients, especially for underdiagnosis of conditions (Delbaere & Smith, 2006). On the
other hand, the opposing position claims DTCA leads to many drawbacks for the public;
which include misled patients regarding drug information, interference with physician
decisions in prescribing, and drug overutilization (Ventola, 2011).
According to the Centers for Medicare and Medicaid Service (CMS), prescription
drug costs increased to $297.7 billion in 2014 with a 12.2% growth rate compared to 2013
(CMS, 2014). Rising healthcare expenditure is a problematic issue in the U.S. health care
delivery system. The growing trend of DTCA could worsen the cost containment for
prescription drug costs (Donahue et al., 2007).
The purpose of this research seeks to assess the current practice of DTCA in the U.S.
health care system and help demonstrate the effect of DTCA on patients, physicians, and drug
utilization.
METHODOLOGY
The methodology is a literature review, which followed a systematic review approach. The
literature review consists of three distinct stages: (1) identifying relevant databases and
keywords, (2) creating inclusion criteria, analyzing text for relevancy, and examining the
literature data; and (3) classifying proper categories.
Step 1: Literature search and collection

The literature review search consisted of four databases, which included Marshall
University EBSCOhost database, ScienceDirect, PubMed, and Google Scholar.
The keywords used in searching included: “direct-to-consumer advertising and expenditure or
spending," “DTCA and expenditure or spending," “prescription drug advertising or DTCA
and drug utilization," “DTCA and effect," and “prescription drug and spending."
Step 2: Literature analysis and inclusion criteria
Inclusion criteria for the literature or studies included: written in English, research
studies explicitly conducted in the U.S. or New Zealand, and published year from 2000 to
2017. The literature published from 2006 or later was more favorable as it would provide a
trend in DTCA promotion during the past 11 years. Eighty-seven articles met the inclusion
criteria, with 42 of the articles selected for this review.
Step 3: Literature Categorization
The selected review articles or studies were categorized based on the conceptual
framework and specific subheadings, which included The Emerging of Online DTCA and
Trend for Pharmaceutical Advertising; Prescription Drug Coupons, A New Form of DTCA;
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DTCA Effect Relationship Between Patient and Physician and Patient’s Satisfaction; and The
DTCA and Drug Utilization.
Conceptual Framework
The conceptual framework was adapted from Frosh, Grande, Tarn and Kravitz (2010)
and constructs on the increasing protagonist of patients as consumers. Active participation of
patients in clinical medical decision-making in the recent years is transforming patients from
passive to active recipients of care. (Figure 1) DTCA by the pharmaceutical industry
empowers consumers to enhance their involvement. Patients often request physicians to
prescribe specific drugs because of DTCA marketing through high or low-quality
information. Patient requests for particular drugs are driven by their past medical history,
education, and advertisements the provide inaccurate and incomplete information or by
sufficient and balanced information. These patient requests affect the physician-patient
relationship because the physician may be unable to order the prescription requested by the
patient. While DTCA enhances the patient’s involvement, the extent of patient participation
varies based on the quality of the information the patient accesses. Additionally, DTCA can
result in decreasing the underprescribing of prescription medications as well as contribute to
patient adherence to prescribed medications. DTCA benefits consumers by reminding them of
their prescriptions, medical conditions and not leading to a specific prescription request
(Figure 1).

------------------------------------------------------------------------------------------------------------FIGURE 1 ABOUT HERE
------------------------------------------------------------------------------------------------------------RESULTS
The Emerging of Online DTCA and Trend for Pharmaceutical Advertising
With the growth of Internet-based information, consumers began actively searching
for information via online channels, including searches for medical information. Growth
estimates projected a double-digit gain, between 2010 -2015, for expenditures of internetbased pharmaceutical advertising, or eDTCA, (Liang & Mackey, 2011). The advantage of
eDTCA is the ability for pharmaceutical companies to spread advertisement globally via
multiple channels such as websites, satellite TV, and social media (Mintzes, Morgan, &
Wright, 2009).
Mackey, Cuomo, and Liang (2015) conducted research investigating the information
regarding DTCA expenditures by pharmaceutical firms from 2005 to 2009. The data,
collected from multiple marketing data firms such as IMS Health, Nielsen Co., Cegedim
Strategic Data, and Kantar Media, allowed for analysis of total spending of DTCA and
spending for each DTCA sub-category, which included television, print media, radio, outdoor
ads, and internet (eDTCA).
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The total spending of DTCA by pharmaceutical firms decreased from $4.8 billion in
2005 to $4.4 billion in 2009, equating to a 7.83% decline from 2005 to 2009. The most
significant spending of DTCA sub-category during this period was television, with
approximately $2.9 billion spent in 2009. However, this channel showed a decrease in
expense by 13.20% from 2005 to 2009. Even though eDTCA sub-category accounted for a
small amount of spending in total DTCA, it experienced a three-digit growth of 109 % in the
same period. (Mackey et al., 2015). Additionally, the IMS Institute of Health Informatics
estimated drug expenditure in the US of about $374 billion in 2014 and global spending on
medications would reach $1.4 trillion by 2020 (IMS, 2014). According to Kantar Media,
DTCA spending grew 4.6% from 2015 ($6.09 billion) to $6.38 billion in 2016. The television
category demonstrated the growth of about 4%, while there was relatively no change in the
internet category and the print media, radio, and outdoor group increased about 7 %. (Table
1)
-----------------------------------------------------------------------------------------------------------Table1: DTCA expenditure in 2015 and 2016
--------------------------------------------------------------------------------------------------Kornfield et al. (2015) reported a significant decrease in household exposure to DTCA
via television from 2007 to 2013. The average of televised DTCA household exposure was
195.3 times per month in 2007 compared to 111.1 times per month in 2011, which indicated a
43% reduction from 2007 to 2013. However, the household exposure of DTCA for depression
medications increased 8.6 times per month in 2007 to 11.3 times per month in 2011
(Kornfield et al., 2015). The emergence of the online media advertisement contributes to a
reduction in televised DTCA. (Liang & Mackey, 2011).

Prescription Drug Coupons, a new form of DTCA
The Prescription Drug Coupon (PDC) is an innovative form of pharmaceutical
marketing offering exclusive discounts for branded drugs for patients having private
insurance or patients paying out-of-pocket (Gagnon & Lexchin, 2008). The ideal goal of PDC
is to alleviate the burden of cost related expenses of expensive branded drugs that might result
in non-adherence and further complications. Access of the PDC is through a variety of media
such as pamphlets in a physician office, websites, and eCoupons (Grande, 2012).
PDCs associate with the promotion of expensive branded drugs. According to Grande
(2012) the result of an internet search, using keywords “prescription drug coupon” and the
Google search engine, resulted in 9 products from top-10 selling drugs during November
2011 to November 2012. Six of the ten products had “black box” warnings relating to
potentially serious complications. Furthermore, of concern became the question of whether
PDC would indeed lead to lower prescription drug expenditures and/or appropriate use of
medication (Gagnon & Lexchin, 2008). For example, Lipitor, a product engaged in PDC,
offering a discount of $75 per month in 2014, resulted in an overall cost of $1,119.6 per year.
However, Lipitor can be replaced with a generic product with an overall total expense of $192
per year in 2014, providing savings of $927.60 per year in 2014 (Mackey, Yagi, & Liang,
2014). Also, research indicates that patients exposed to PDC advertising are more likely to
ask physicians for specific prescription drugs and have shown a more favorable attitude
towards those products (Bhutada, Cook, and Perri, 2009).
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DTCA Effect Relationship between Patient and Physician and Patient’s Satisfaction
DTCA alters the way patients and physicians interact with each other in the U.S.
health care system (Potter & McKinlay, 2005). DTCA exposure allows for increases in
patient demand for specific prescription drugs by increasing the opportunity for a patient to
ask a physician about those explicit drugs. Additionally, these authors showed that 43% of
patients, who mentioned DTCA drugs during their last physician office visit, received the
medication they requested (Weissman et al., 2004).
The effect of DTCA on patient satisfaction varies due to age and severity of conditions
(Blose & Mack, 2009). A study conducted by using vignettes indicates that denial of a
patient’s request for a specific prescription affects patient satisfaction, trust, and commitment;
however, the expectation of receiving the medication did not change those factors. (Shah,
Bentley, & McCaffrey, 2006).
Lewin (2013) studied factors affecting patient satisfaction within patient groups who
discussed information from DTCA with their physicians. The data, collected via random-digit
telephone interview, provided results showing that receiving a diagnosis was not associated
with increased patient satisfaction, yet receiving a prescription was associated with higher
patient satisfaction. Furthermore, patients receiving a medication related to DTCA were more
likely to report higher satisfaction by 42.2% compared with those receiving another
prescription. Finally, patients not receiving a drug-related to DTCA were more likely to have
higher satisfaction if they were explainedg the denial of the DTCA prescription (Lewin,
2013).
The DTCA and Drug Utilization
DTCA encourages patients to seek treatment with physicians, especially for underdiagnosed conditions and conditions associated with social stigmas, such as depression
(Holmer, 2002). On the contrary, DTCA can lead to overdiagnosis and drug overutilization
which might ultimately increase adverse drug reactions (Ross, & Kravitz, 2013). Currently,
there has been no sufficient evidence identifying whether DTCA causes more harm than
benefit or vice versa (Mintzes, 2012; Law, Majumdar, & Soumerai, 2008).
Irritable bowel syndrome (IBS) is a chronic condition affecting roughly 10% of the
US population; however, only a small number of patients seek treatment due to low public
awareness, social stigma, and absence of a practical solution (Cremonini & Talley, 2005).
Tegaserod was an effective medication for irritable bowel syndrome. Tegaserod, heavily
marketed between 2005 to 2007, was suspended from the market in March 2007 due to its
significant risk of heart conditions (US FDA, 2008). DTCA of Tegaserod increased the public
awareness of IBS, increased physician visits for this condition, and increased the number of
scripts written for Tegaserod (Dorn, Farley, Hansen, Shah, & Sandler, 2009).
The effect of DTCA increasing the number of prescriptions can be appreciated in
many drug classes, including statins, H2 receptor antagonists, and triptans. The beneficial
outcome of DTCA on the increase in prescriptions has been ambiguous and may be difficult
to evaluate. In other words, if the rise in prescriptions results from more awareness and usage
of first-line medications, DTCA would be considered beneficial; conversely, it would be
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detrimental if DTCA promoted the inappropriate use of second-line drugs (Skeldon,
Kozhimannil, Majumdar, & Law, 2015).
Tamsulosin (Flomax) and Dutasteride (Adovart) were first lines and second line
medications for benign prostatic hypertrophy respectively. Skeldon et al. (2015) examined the
expenditure of DTCA, the web search interest, and drug utilization for both drugs from
January 2003 to December 2007. DTCA spending for Tamsulosin was $139 million from
2003 to 2007 and was $231 million for Dutasteride, respectively. The effect of both
campaigns was Tamsulosin, and Dutasteride resulted in an aggregate increase of both product
awareness, which it was detected by web search interest, and drug utilization. For example,
the DTCA of Dutasteride (second line medication) not only increased the utilization trend of
Dutasteride but also increased the use of Tamsulosin (first line medication) nearly two times
compared to Dutasteride. Thus, DTCA of competing products was likely to show beneficial
outcomes of increased appropriate prescriptions by improving the awareness rather than the
inappropriate use of a second line medication (Skeldon et al., 2015)
DISCUSSION
Those supporting and opposed to DTCA have criticized the practice of DTCA in the U.S.
However, there is a minimal chance that DTCA would fade away in pharmaceutical
advertising practices in the US. The results from Mackey et al. (2015) have shown a slight
decrease in overall spending of DTCA by 7.83 % during 2005 to 2009, but the shifting from
one type of DTCA to another less expensive form of DTCA is the possible causation of this
decrease. According to the data presented by Kantar media, the television channel has served
as the most important channel of DTCA as it consisted of approximately 65% of total
spending with $ 4.1 billion in 2016. The television sub-category experienced an increase of
4% from 2015-2016, while the internet sub-category showed almost no change with a
decrease of one million to $515 million in digital media according to this source. However,
this amount does not consider the expenditure of websites, web videos, web audio, sponsored
links, social media (which is in basically free), search engine marketing, mobile applications,
and emails. A 2013 study reported that electronic internet promotion grew 109% between
2005 to 2009 to $117 million (Kornfield, Donohue, Berndt, & Alexander, 2013) and the
findings of this study suggest that online DTCA has increased its spending at least 4.4 times
from 2009 to 2016.
Liang and Mackey (2011) reported that the internet was the most popular source among
consumers who searched for health-related information.

PDCs have been another trend that has emerged in DTCA in the U.S. that may have
caused detrimental effects on patients since they are heavily involved with “black box”
warnings for prescription drugs. Even though the pharmaceutical companies claim that PDCs
intended to promote accessibility and adherence to medications, it was more likely for
extending product life cycles, since most of the prescription drugs available with PDC are
patent expired or close to the patent expiration date. If this trend of PDC continues to gain
popularity, it might increase the cost of prescription drugs by promoting more expensive
drugs, especially brand name drugs that could be substituted with lower expense generic
drugs regardless of discount.

7

DTCA appeared to affect the way patients and physicians interact with each other.
DTCA increased demand for specific drugs and patients have become engaged in mentioning
particular medications to their physicians. Furthermore, those who received the medication
showed greater satisfaction than other patients, who did not (Lewin, 2013; Weissman et al.,
2004). This situation could put pressure on physicians desiring to satisfy their patient's
requests, leading to inappropriate prescribing thereby, resulting in increased unsuitable drug
utilization. The survey on physicians by Robinson et al. reported that DTCA has produced an
increased inappropriate prescription volume and has affected prescribing patterns (Robinson
et al., 2004).
DTCA can increase the drug utilization by raising the awareness of patients regarding
a specific disease, especially conditions that are associated with social stigma. However, this
increase of drug utilization has both beneficial and harmful consequences. Tegaserod
prescriptions were increased by the effect of DTCA and were then withdrawn from the market
in 2007 due to a significant risk of heart conditions. This similar issue was also found earlier
with Vioxx in 2004. There were no strict regulations for DTCA on the new drugs, so full
safety profiles need to be established (Liang & Mackey, 2011).
On the other hand, the benefits of DTCA has been realized in the case of Tamsulosin
and Dutasteride. The promotion of Dutasteride, which was the second line therapy of benign
prostatic hyperplasia, resulted in increased awareness of the condition and the increase in the
prescription volume of Tamsulosin, which is the first line therapy. Thus, the promotion of
Dutasteride through DTCA could be considered beneficial by increasing diagnosis and
increasing appropriate drug utilization.
DTCA can have a significant impact on the healthcare system since it enhances
awareness to the public of devices or therapies that are very expensive and may not be the
standard of care for specific disease processes. Ball and Mackert (2013) reported that
pharmaceutical advertisers use powerful tactics such emotional appeals as an opportunity to
overcome distrust and to compete for patient's attention with other pharmaceutical ads. DTCA
can cause potential harm; primarily by diminishing the time involved in the discussion of the
DTCA information brought by the patient to the medical visit.
The trend of DTCA has been growing and has resulted in increased drug utilization
through multiple mechanisms, which included increase demand of the patient for a specific
drug, raise awareness regarding under-diagnosed condition, and promote dialogue between
physician and patient. The content for each DTCA may result in different outcomes regarding
the appropriateness of drug utilization.
The limitations of the study included: limited current information of DTCA spending
from the pharmaceutical companies that were available to the public. There was a lack of the
quantitative data on the effect of pharmaceutical DTCA. Thus it was difficult to evaluate the
actual impact of DTCA on drug utilization. Additionally, DTCA has been a very subjective
topic that is based on individual opinion so that it can be affected by researchers and
publication bias. Future research should examine the association between DTCA spending
and drug utilization. A systematic review and a meta-analysis should be performed to
have a more precise measurement of the effects (i.e., expenditure, drug utilization, and
cost) of DTCA in the US healthcare delivery system. Also, future research is needed in
recognizing the five steps of patient's decision-making and if the effects of DTCA would
be equivalent across the five steps (Mukherjee, Limbu and Wanasika 2013)
8

CONCLUSION
The online channel has been a critical advertising portal for DTCA by pharmaceutical firms.
The DTCA of pharmaceutical companies has shown mixed results of potential benefits and
harm.
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Figure 1: Conceptual Framework:
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Table1: DTCA expenditure in 2015 and in 2016 (Kantar Media., 2016)

DTCA category

2015 US Media
expenditure
(millions)
$3,908

2016 US Media
expenditure
(millions)
$4,064

Change
(%)

Print media + radio +
outdoor ads
Internet

$1669

$1795

7

$516

$515

-0.2

Total DTCA

$6,093

$6,375

4.6

Television

4
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